iCAD Introduces ProFound AI™ for 2D Mammography in Europe
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France
NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France.
“iCAD is at the forefront of the fight against breast cancer. We bring powerful solutions to physicians across Europe so women everywhere can benefit from earlier detection,” explains Michele Debain, MBA, Sr. Director, Business Development Europe, iCAD. “Our first ProFound AI product was for tomosynthesis; this solution was created to help physicians overcome their workflow issues of reading extensive amounts of data and reduce the likelihood of missing malignancies. Today, we are thrilled to introduce our second ProFound AI product for 2D Mammography, which promises to assist physicians in all breast screening exams, especially the challenging dense breast cases, to bring precise detection and reduce false positives. ProFound AI for Mammography is an extremely valuable tool for women, physicians and all breast screening practices.”
ProFound AI is available for both mammography and tomosynthesis modalities; it is a high-performance, deep-learning, breast cancer detection and workflow solution that offers benefits to radiologists and patients alike. ProFound AI for DBT is clinically proven to improve cancer detection rates by 8 percent, reduce unnecessary patient recall rates by 7.2 percent, and slash reading time for radiologists by 52.7 percent and up to 57.4 percent for dense breast 3D image analysis.1
“The arrival of the ProFound AI platform has completely changed the way we read tomosynthesis cases. It is a very powerful and extremely useful tool that improves our diagnostic confidence; especially for subtle lesions and dense breasts,” according to Dr. Patrick Toubiana, Radiologist, President and Cofounder at the C.S.E. Centre Imagerie Médicale Numérique in Paris. “In addition, ProFound AI allows us to optimize our workflow for better reading comfort and a reduction of the interpretation time of the tomosynthesis slices. Today, ProFound AI is a real asset in our daily practice that we could not do without.”
ProFound AI for 2D Mammography and ProFound AI for DBT were designed to rapidly and accurately analyze each image and provide radiologists with key information, such as certainty of finding lesion and case scores, which assists in clinical decision-making and prioritizing caseloads. Featuring the latest in deep-learning artificial intelligence, the platform also allows for continuously improved performance via ongoing updates.
“The ProFound AI software platform is the result of many years of research and development to create a deep-learning algorithm that analyzes each image with unrivaled accuracy,” according to Stacey Stevens, President of iCAD. “With more than 4,000 sites worldwide to-date, the growing adoption of our technology demonstrates iCAD’s rapidly expanding global presence and reaffirms our company’s commitment to improving women’s health worldwide.”
ProFound AI for DBT was FDA cleared, CE marked, and Health Canada licensed in 2018. ProFound AI for 2D Mammography is pending CE Mark in the EU. For more information, visit www.icadmed.com.
- Hoffmeister, J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed June 4, 2019 via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Jessica Burns, iCAD
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Value Asset Management PLC Announces Launch of GBP 1 Million Equity Private Placement22.8.2019 19:09:00 CEST | Press release
Value Asset Management PLC Announces Launch of GBP 1 Million Equity Private Placement London, August 22nd, 2019. Value Asset Management PLC (VAM PLC) VAM PLC, a residential property developer within the Republic of Ireland is pleased to announce the launch of an equity private placement for gross proceeds of up to GBP 1 million. The private placement will be for up to 10,000,000 new shares in the company at a value of 10p each. Burlingtons Group, headquartered in London, have been formally engaged to conduct the placing which is intended to close by October 31st, 2019. Burlingtons Group has an extensive client and contact base across the globe through its international office base and represents many high-net-worth individuals, private investment funds, developers and banks. Burlingtons Legal LLP, which is also a member of Burlingtons Group, is separately engaged by VAM PLC to act as Bond Trustee to its “Value Asset Management PLC – 6.5% Secured Corporate Bonds 31/07/23 EUR 1 A” (ISIN:
Banks net position in the Riksbank22.8.2019 16:47:00 CEST | Press release
AUG 22, 2019 SEK MILLION LENDING BORROWING 247
DNO ASA: FAPE01 bond buyback22.8.2019 16:35:00 CEST | Press release
Oslo, 22 August 2019 - DNO ASA, the Norwegian oil and gas operator, today purchased USD 3.0 million in nominal value of FAPE01 bonds (ISIN NO0010811268) originally issued by Faroe Petroleum plc, and renamed DNO North Sea plc. The bonds were purchased at a price of 107.00. Following the bond buyback and prior cancellations due to put option exercises, USD 65.2 million in nominal value of the FAPE01 bonds remain outstanding with DNO ASA holding the balance of USD 20.6 million. The FAPE01 bonds mature on 28 April 2023. For further information, please contact: Media: firstname.lastname@example.org (mailto:email@example.com) Investors: firstname.lastname@example.org (mailto:email@example.com) Tel: +47 23 23 84 80 -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East-North Africa region and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdista
Vaisala Digital Renews Focus and Reorganizes Operations22.8.2019 16:30:00 CEST | Press release
Vaisala Press Release August 22, 2019 Vaisala Digital Renews Focus and Reorganizes Operations To drive business performance and innovation speed, Vaisala Digital focuses on transportation, renewable energy, lightning, and data-driven operations, steps up its investments in development, and reorganizes its structure and operations. Vaisala sets a new direction for its digital business with investments into new assets, capabilities, and structure to develop industry leading digital solutions to support its customers to make best decisions in weather critical operations. In addition to the recently announced acquisition of Foreca’s professional B2B weather services business, Vaisala focuses on building up enhanced competences in machine learning and artificial intelligence, consolidates its data centers into two locations, and opens a new Vaisala Digital site in Keilaniemi, Espoo, to drive co-innovation with the software research and development community. “The acquisition of Foreca’s pro
Avance Gas Holding Ltd – Notice of Annual General Meeting22.8.2019 16:27:00 CEST | Press release
Avance Gas Holding Ltd – Notice of Annual General Meeting Avance Gas Holding Ltd (OSE: AVANCE) announces that its 2019 Annual General Meeting will be held on September 13, 2019. A copy of the Notice of Annual General Meeting and including the Company`s Consolidated Financial Statements for 2018 can be found in the links below and on our website at www.avancegas.com. For further queries, please contact: Peder C. G. Simonsen, CFO Tel: +47 22 00 48 15 / Email: firstname.lastname@example.org ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGC), and operates a fleet of fourteen modern ships For more information about Avance Gas, please visit: www.avancegas.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments AGM Notice Avance Gas Avance Gas Annual-Report-20
Stämmokommuniké från extra bolagsstämma i Vostok New Ventures Ltd22.8.2019 16:00:00 CEST | Pressemelding
Extra bolagsstämma i Vostok New Ventures Ltd (”Bolaget”) hölls onsdagen den 22 augusti 2019 kl. 14.00 i Advokatfirman Vinges lokaler, Stureplan 8 i Stockholm. Stockholm, Aug. 22, 2019 (GLOBE NEWSWIRE) -- På extra bolagsstämma hade aktieägarna att ta ställning till om ett nytt aktiebaserat incitamentsprogram skulle antas för vissa ledande befattningshavare och nyckelpersoner inom Vostok New Ventures-koncernen. Följande beslut fattades: Stämman beslutade, i enlighet med styrelsens förslag, att anta ett femårigt prestationsbaserat incitamentsprogram som bygger på samma ekonomiska egenskaper för deltagarna och samma kriterier för att mäta prestation som de befintliga SDB-baserade incitamentsprogrammen, men som har utformats för att minska kostnaderna såväl för Bolaget som för deltagarna. Stämman beslutade, i enlighet med styrelsens förslag, att ändra Bolagets Bye-Laws (bolagsordning), varigenom en ny aktieklass, incitamentsaktier, införs. Stämman beslutade, i enlighet med styrelsens försla